2022 Year In Review for investor audiences

Video of Regeneron leaders reflecting on 2022 achievements.

Video - Intro Video

Regeneron leaders reflect on 2022 accomplishments. Learn more about our approved medicines, including Prescribing Information.

For 35 years, Regeneron has remained steadfast in our mission to use the power of science to repeatedly bring new, life-transforming medicines to patients.

Our products and pipeline are designed to help patients across many disease areas, and we are always looking for ways to accelerate and improve the traditional drug development process through our innovative technologies and ambitious research initiatives.

From conducting one of the world’s largest genetics sequencing efforts, to expanding on our proprietary VelociSuite^® technologies, to advancing novel and investigational bispecific antibodies, we are applying our homegrown tools and relentless spirit to discover new targets and potential treatments, advance our clinical studies and help reach people with serious diseases around the world.

BRINGING OUR SCIENCE-LED APPROACH TO
PATIENTS, COMMUNITIES AND SOCIETY

(as of April 2023)

9

FDA-approved
medicines

~35

investigational medicines in clinical development

~60

countries with Regeneron clinical trials

~2 million

exomes sequenced
by RGC^®

~11,900

Regeneron employees worldwide at year end

7

countries with Regeneron offices

550

partnerships with small businesses and diverse suppliers

180+

global and U.S. patient advocacy and professional societies engaged across more than 35 diseases

4

consecutive years on the Dow Jones Sustainability World Index

100%

of Regeneron-owned sites maintained zero waste-to-landfill

Excludes construction and demolition waste

1 ton

of single-use latex and nitrile gloves recycled into new items at our Rensselaer site

~20K

hours of employee community service through our annual Day for Doing Good

~1.7 million

students engaged
in Regeneron STEM
initiatives since 2020

9

employee resource groups providing inclusive professional development and leadership opportunities

Regeneron employees engaged in community initiative.

DOING WELL BY DOING GOOD

Corporate responsibility is at the heart of everything we do and every decision we make. At Regeneron, we use our unique knowledge and expertise to improve the lives of people with serious diseases, as well as to benefit society, the economy and our environment. We apply our science-led approach to advance our global 2025 responsibility goals, foster a culture of integrity and excellence and build sustainable communities. By addressing issues that matter most to our business and society, we are working toward building resiliency and improving our world. Go deeper in our 2022 Responsibility Report.

ACCESS OUR RESPONSIBILITY REPORT

Proxy Statement and Notice of Annual Shareholder Meeting 2023.

READ OUR 2023 PROXY STATEMENT

Learn more about our annual updates for 2023 in our Proxy.

PROXY STATEMENT

REVIEW PAST DIGITAL REPORTS

This Year in Review contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Please see Regeneron’s press release announcing its financial and operating results for the fourth quarter and full year 2022 for important information about Regeneron’s forward‑looking statements.

NEXT: ABOUT OUR MEDICINES